Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Jaktinib for Steroid-Refractory Acute Graft-Versus-Host Disease
NCT04971551Phase 2Not yet recruiting
- Sponsor
- Zelgen
- Start
- Dec 2024
- Primary completion
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of jaktinib in Acute Graft-Versus-Host Disease (aGvHD), sponsored by Zelgen. Primary endpoint: Overall Response Rate at 28 days. Planned start Dec 2024; status: not yet recruiting.
02
Drugs
jaktinib
03
Conditions
Acute Graft-Versus-Host Disease (aGvHD)
Beyond the preview
Go deeper on NCT04971551.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04971551.